基本信息
浏览量:44
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
His research focus has been on translational immuno-oncology and clinical trials. In his main study titled, Immune pathway changes pre and post checkpoint inhibitor therapy in metastatic urothelial carcinoma, aims at elucidating important immune factors affecting response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma who progressed on those treatments. In addition, he is finalizing a phase I trial of a DC-vaccine trial targeting CAIX in patients with metastatic renal cell carcinoma, which was recently presented at GU ASCO, and for which he received the Merit Award. Important corollary studies are underway to understand the immune reactivity of the vaccine therapy, and the immune response in the study cohort. This will inform refining the treatment protocol and perhaps provide some evidence for combination approaches with immune checkpoint inhibitors.
研究兴趣
论文共 92 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Harshraj Leuva,George Moran, Nader Jammaleddine, Mina Maseeha,Mengxi Zhou,Yunju Im,Ta-Chueh Melody Rosenberg, Yeun-Hee Anna Park,Carol Luhrs,Susan E. Bates,Izak Faiena
Research Square (Research Square)no. 3-4 (2024): 59-68
Harshraj Leuva,Mengxi Zhou, Rumen Stamatov,Benjamin A. Teply,Ta-Chueh Melody Rosenberg, Carol A. Luhrs,Prabhjot Singh Mundi,Yeun-Hee Anna Park,Susan Elaine Bates,Izak Faiena,Antonio Tito Fojo
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 5076-5076
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 5085-5085
加载更多
作者统计
#Papers: 92
#Citation: 3854
H-Index: 21
G-Index: 62
Sociability: 6
Diversity: 2
Activity: 12
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn